Mast Therapeutics, Inc. (SVRA) Receives Consensus Rating of “Buy” from Analysts

Shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) have earned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $24.25.

SVRA has been the subject of several research reports. Zacks Investment Research cut Mast Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. Canaccord Genuity boosted their price target on Mast Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 30th. ValuEngine cut Mast Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Jefferies Group initiated coverage on Mast Therapeutics in a report on Friday, September 22nd. They issued a “buy” rating and a $20.00 target price for the company. Finally, Roth Capital restated a “buy” rating and issued a $40.00 target price on shares of Mast Therapeutics in a report on Wednesday, September 27th.

Shares of Mast Therapeutics (NASDAQ:SVRA) traded down $0.09 on Tuesday, hitting $14.84. The company had a trading volume of 100,664 shares, compared to its average volume of 190,054. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $17.19. The stock has a market capitalization of $455.38, a PE ratio of -4.42 and a beta of 0.19.

In related news, Director Yuri Pikover bought 50,000 shares of the company’s stock in a transaction on Friday, October 27th. The stock was bought at an average cost of $7.85 per share, for a total transaction of $392,500.00. Following the acquisition, the director now directly owns 150,000 shares in the company, valued at $1,177,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.93% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/01/mast-therapeutics-inc-svra-receives-consensus-rating-of-buy-from-analysts.html.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply